Dysregulation of dynorphins in Alzheimer disease

Neurobiology of Aging

Volumn 28, Issue 11, 2007, Pages 1700-1708

  Yakovleva, T ^a   Marinova, Z ^a   Kuzmin, A ^a   Seidah, N G ^b   Haroutunian, V ^c   Terenius, L ^a   Bakalkin, G ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

7B2; Alzheimer disease; Cognition; Dynorphin; Excitotoxicity; Neurodegeneration; Pro hormone convertase 2; Prodynorphin

Indexed keywords

DYNORPHIN A; DYNORPHIN B; NEUROPEPTIDE; NOCICEPTIN; PRODYNORPHIN; PROTEIN PRECURSOR;

AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; BRAIN CORTEX; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOIMMUNOASSAY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; DYNORPHINS; ENDORPHINS; FEMALE; HUMANS; MALE; NERVE DEGENERATION; OPIOID PEPTIDES; UP-REGULATION;

EID: 34548595584     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2006.07.002     Document Type: Article

References (74)

1. Allen R.G., Peng B., Pellegrino M.J., Miller E.D., Grandy D.K., Lundblad J.R., et al. Altered processing of pro-orphanin FQ/nociceptin and pro-opiomelanocortin-derived peptides in the brains of mice expressing defective prohormone convertase 2. J Neurosci 21 (2001) 5864-5870
2. Bakalkin G., Telkov M., Yakovleva T., and Terenius L. [Leu5]enkephalin-encoding sequences are targets for a specific DNA-binding factor. Proc Natl Acad Sci USA 92 (1995) 9024-9028
3. Barg J., Belcheva M., Rowinski J., Ho A., Burke W.J., Chung H.D., et al. Opioid receptor density changes in Alzheimer amygdala and putamen. Brain Res 632 (1993) 209-215
4. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163 (2000) 495-529
5. Benjannet S., Rondeau N., Paquet L., Boudreault A., Lazure C., Chretien M., et al. Comparative biosynthesis, covalent post-translational modifications and efficiency of prosegment cleavage of the prohormone convertases PC1 and PC2: glycosylation, sulphation and identification of the intracellular site of prosegment cleavage of PC1 and PC2. Biochem J 294 (1993) 735-743
6. Berman Y., Ageyeva L., Veksler B., Wood D., and Devi L.A. Dynorphin A processing enzyme: tissue distribution, isolation and characterization. J Biochem 125 (1999) 641-647
7. Berman Y., Mzhavia N., Polonskaia A., Furuta M., Steiner D.F., Pintar J.E., et al. Defective prodynorphin processing in mice lacking prohormone convertase PC2. J Neurochem 75 (2000) 1763-1770
8. Christensson-Nylander I., Nyberg F., Ragnarsson U., and Terenius L. A general procedure for analysis of proenkephalin B derived opioid peptides. Regul Pept 11 (1985) 65-76
9. Cleary J.P., Walsh D.M., Hofmeister J.J., Shankar G.M., Kuskowski M.A., Selkoe D.J., et al. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 8 (2005) 79-84
10. Davis K.L., Mohs R.C., Marin D.B., Purohit D.P., Perl D.P., Lantz M., et al. Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psychiatry 56 (1999) 981-987
11. Davies P., Katzman R., and Terry R.D. Reduced somatostatin-like-immunoreactivity in cerebral cortex from cases of Alzheimer's disease and Alzheimer's senile dementia. Nature 288 (1980) 279-280
12. Day R., and Akil H. The posttranslational processing of prodynorphin in the rat anterior pituitary. Endocrinology 124 (1989) 2392-2405
13. Day R., Lazure C., Basak A., Boudreault A., Limperis P., Dong W., et al. Prodynorphin processing by proprotein convertase 2. Cleavage at single basic residues and enhanced processing in the presence of carboxypeptidase activity. J Biol Chem 273 (1998) 829-836
14. Faden A.I. Dynorphin increases extracellular levels of excitatory amino acids in the brain through a non-opioid mechanism. J Neurosci 12 (1992) 425-429
15. Gabriel S.M., Davidson M., Haroutunian V., Powchik P., Bierer L.M., Purohit D.P., et al. Neuropeptide deficits in schizophrenia vs. Alzheimer's disease cerebral cortex. Biol Psychiatry 39 (1996) 82-91
16. Gottfries C.G. Alzheimer's disease and senile dementia: biochemical characteristics and aspects of treatment. Psychopharmacology (Berl) 86 (1985) 245-252
17. Greenamyre J.T., and Young A.B. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 10 (1989) 593-602
18. Haroutunian V., Perl D.P., Purohit D.P., Marin D.B., Khan K., Lantz M., et al. Regional distribution of neuritic plaques in non-demented elderly and cases of very mild Alzheimer's disease. Arch Neurol 55 (1998) 1185-1191
19. Hauser K.F., Aldrich J.V., Anderson K.J., Bakalkin G., Christie M.J., Hall E.D., et al. Pathobiology of dynorphins in trauma and disease. Front Biosci 10 (2005) 216-235
20. Hauser K.F., Knapp P.E., and Turbek C.S. Structure-activity analysis of dynorphin A toxicity in spinal cord neurons: intrinsic neurotoxicity of dynorphin A and its carboxyl-terminal, non-opioid metabolites. Exp Neurol 168 (2001) 78-87
21. Hiramatsu M., Murasawa H., Mori H., and Kameyama T. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous κ-opioid receptor agonist. Brit J Pharmacol 123 (1998) 920-926
22. Hughes C.P., Berg L., Danziger W.L., Coben L.A., and Martin R.L. A new clinical scale for the staging of dementia. Brit J Psychiatry 140 (1982) 566-572
23. Hugonin L., Vukojević V., Bakalkin G., and Gräslund A. Membrane leakage induced by dynorphins. FEBS Lett 580 (2006) 3201-3205
24. Iguchi H., Chan J.S., Seidah N.G., and Chretien M. Evidence for a novel pituitary protein (7B2) in human brain, cerebrospinal fluid and plasma: brain concentrations in controls and patients with Alzheimer's disease. Peptides 8 (1987) 593-598
25. Jiang H.K., Owyang V.V., Hong J.S., and Gallagher M. Elevated dynorphin in the hippocampal formation of aged rats: relation to cognitive impairment on a spatial learning task. Proc Natl Acad Sci USA 86 (1989) 2948-2951
26. Johanning K., Juliano M.A., Juliano L., Lazure C., Lamango N.S., Steiner D.F., et al. Specificity of prohormone convertase 2 on proenkephalin and proenkephalin-related substrates. J Biol Chem 273 (1998) 22672-22680
27. Khachaturian H., Lewis M.E., Haber S.N., Houghten R.A., Akil H., and Watson S.J. Prodynorphin peptide immunocytochemistry in rhesus monkey brain. Peptides 6 Suppl. 2 (1985) 155-166
28. Khachaturian H., Lewis M.E., Schäfer M.K.H., and Watson S.J. Anatomy of the CNS opioid systems. TINS 8 (1985) 111-119
29. Kuzmin A, Madjid N, Terenius L, Ogren SO, Bakalkin G. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice. Neuropsychopharmacology, 2005, [Epub ahead of print].
30. LaFerla F.M. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 3 (2002) 862-872
31. Louzada P.R., Lima A.C., Mendonca-Silva D.L., Noel F., De Mello F.G., and Ferreira S.T. Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 18 (2004) 511-518
32. Lue L.F., Kuo Y.M., Roher A.E., Brachova L., Shen Y., Sue L., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 (1999) 853-862
33. Marinova Z., Vukojevic V., Surcheva S., Yakovleva T., Cebers G., Pasikova N., et al. Translocation of dynorphin neuropeptides across the plasma membrane. A putative mechanism of signal transmission. J Biol Chem 280 (2005) 26360-26370
34. Marinova Z., Yakovleva T., Melzig M.F., Hallberg M., Nylander I., Ray K., et al. A novel soluble protein factor with non-opioid dynorphin A-binding activity. Biochem Biophys Res Commun 321 (2004) 202-209
35. Mathieu-Kia A.M., Fan L.Q., Kreek M.J., Simon E.J., and Hiller J.M. Mu-, delta- and kappa-opioid receptor populations are differentially altered in distinct areas of postmortem brains of Alzheimer's disease patients. Brain Res 893 (2001) 121-134
36. Mattson M.P., Cheng B., Davis D., Bryant K., Lieberburg I., and Rydel R.E. Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 12 (1992) 376-389
37. McLean C.A., Cherny R.A., Fraser F.W., Fuller S.J., Smith M.J., Beyreuther K., et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol 46 (1999) 860-866
38. Merg F., Filliol D., Usynin I., Bazov I., Bark N., Hurd Y.L., et al. Big dynorphin as a putative endogenous ligand for the kappa-opioid receptor. J. Neurochem 97 (2006) 292-301
39. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., et al. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41 (1991) 479-486
40. Morris J.C. The clinical dementia rating (CDR): current version and scoring rules. Arch Neurol 43 (1993) 2412-2414
41. Morrison J.H., Rogers J., Scherr S., Benoit R., and Bloom F.E. Somatostatin immunoreactivity in neuritic plaques of Alzheimer's patients. Nature 314 (1985) 90-92
42. Muller L., and Lindberg I. The cell biology of the prohormone convertases PC1 and PC2. Prog Nucl Acid Res Mol Biol 63 (1999) 69-108
43. Nguyen X.V., Masse J., Kumar A., Vijitruth R., Kulik C., Liu M., et al. Prodynorphin knockout mice demonstrate diminished age-associated impairment in spatial water maze performance. Behav Brain Res 161 (2005) 254-262
44. Nikoshkov A., Hurd Y.L., Yakovleva T., Bazov I., Marinova Z., Cebers G., et al. Prodynorphin transcripts and proteins differentially expressed and regulated in the adult human brain. FASEB J 19 (2005) 1543-1545
45. Nylander I., Vlaskovska M., and Terenius L. The effects of morphine treatment and morphine withdrawal on the dynorphin and enkephalin systems in Sprague-Dawley rats. Psychopharmacology (Berl) 118 (1995) 391-400
46. Pearson R.C., Esiri M.M., Hiorns R.W., Wilcock G.K., and Powell T.P. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc. Natl Acad Sci USA 82 (1985) 4531-4534
47. Ploj K., Roman E., Gustavsson L., and Nylander I. Basal levels and alcohol-induced changes in nociceptin/orphanin FQ, dynorphin, and enkephalin levels in C57BL/6J mice. Brain Res Bull 53 (2000) 219-226
48. Risser D., You Z.B., Cairns N., Herrera-Marschitz M., Seidl R., Schneider C., et al. Endogenous opioids in frontal cortex of patients with Down syndrome. Neurosci Lett 203 (1996) 111-114
49. Rockman M.V., Hahn M.W., Soranzo N., Zimprich F., Goldstein D.B., and Wray G.A. Ancient and recent positive selection transformed opioid cis-regulation in humans. PLoS Biol 3 (2005) 1-12 e387
50. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., et al. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat Med 11 (2005) 434-439
51. Sandin J., Georgieva J., Schott P.A., Ogren S.O., and Terenius L. Nociceptin/orphanin FQ microinjected into hippocampus impairs spatial learning in rats. Eur J Neurosci 9 (1997) 194-197
52. Sandin J., Nylander I., Georgieva J., Schott P.A., Ogren S.O., and Terenius L. Hippocampal dynorphin B injections impair spatial learning in rats: a κ-opioid receptor-mediated effect. Neuroscience 85 (1998) 375-382
53. Sandin J., Ogren S.O., and Terenius L. Nociceptin/orphanin FQ modulates spatial learning via ORL-1 receptors in the dorsal hippocampus of the rat. Brain Res 997 (2004) 222-233
54. Sandin J., Tan-No K., Kasakov L., Nylander I., Winter A., Silberring J., et al. Differential metabolism of dynorphins in substantia nigra, striatum, and hippocampus. Peptides 18 (1997) 949-956
55. Shukla V.K., and Lemaire S. Non-opioid effects of dynorphins: possible role of the NMDA receptor. Trends Pharmacol Sci 15 (1994) 420-424
56. Silberring J., Castello M.E., and Nyberg F. Characterization of dynorphin A-converting enzyme in human spinal cord. J Biol Chem 267 (1992) 21324-21328
57. Silberring J., and Nyberg F. A novel bovine spinal cord endoprotease with high specificity for dynorphin B. J Biol Chem 264 (1989) 11082-11086
58. Singh I.N., Goody R.J., Goebel S.M., Martin K.M., Knapp P.E., Marinova Z., et al. Dynorphin A (1-17) induces apoptosis in striatal neurons in vitro through alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor-mediated cytochrome c release and caspase-3 activation. Neuroscience 122 (2003) 1013-1023
59. Snyder E.M., Nong Y., Almeida C.G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-beta. Nat Neurosci 8 (2005) 1051-1058
60. Skilling S.R., Sun X., Kurtz H.J., and Larson A.A. Selective potentiation of NMDA-induced activity and release of excitatory amino acids by dynorphin: possible roles in paralysis and neurotoxicity. Brain Res 575 (1992) 272-278
61. Tang Q., Lynch R.M., Porreca F., and Lai J. Dynorphin A elicits an increase in intracellular calcium in cultured neurons via a non-opioid, non-NMDA mechanism. J Neurophysiol 83 (2000) 2610-2615
62. Tan-No K., Cebers G., Yakovleva T., Hoon Goh B., Gileva I., Reznikov K., et al. Cytotoxic effects of dynorphins through non-opioid intracellular mechanisms. Exp Cell Res 269 (2001) 54-63
63. Tanzi R.E. The synaptic Aβ hypothesis of alzheimer disease. Nat Neurosci 8 (2005) 977-979
64. Terry R.D., Masliah E., Salmon D.P., Butters N., DeTeresa R., Hill R., et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 30 (1991) 572-580
65. Ukai M., Itoh J., Kobayashi T., Shinkai N., and Kameyama T. Effects of the κ-opioid dynorphin A(1-13) on learning and memory in mice. Behav Brain Res 83 (1997) 169-172
66. Vanderah T.W., Laughlin T., Lashbrook J.M., Nichols M.L., Wilcox G.L., Ossipov M.H., et al. Single intrathecal injections of dynorphin A or des-Tyr-dynorphins produce long-lasting allodynia in rats: blockade by MK-801 but not naloxone. Pain 68 (1996) 275-281
67. Vieau D., Linard C.G., Mbikay M., Lenne F., Chretien M., Luton J.P., et al. Expression of the neuroendocrine cell marker 7B2 in human ACTH secreting tumours. Clin Endocrinol (Oxf) 36 (1992) 597-603
68. Wall P.M., and Messier C. Concurrent modulation of anxiety and memory. Behav Brain Res 109 (2000) 229-241
69. Wang J., Dickson D.W., Trojanowski J.Q., and Lee V.M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158 (1999) 328-337
70. Weber E., Roth K.A., and Barchas J.D. Immunohistochemical distribution of α-neo-endorphin/dynorphin neuronal systems in rat brain: evidence for colocalization. Proc Natl Acad Sci USA 79 (1982) 3062-3066
71. Westphal C.H., Muller L., Zhou A., Zhu X., Bonner-Weir S., Schambelan M., et al. The neuroendocrine protein 7B2 is required for peptide hormone processing in vivo and provides a novel mechanism for pituitary Cushing's disease. Cell 96 (1999) 689-700
72. Winsky-Sommerer R., Grouselle D., Rougeot C., Laurent V., David J.P., Delacourte A., et al. The proprotein convertase PC2 is involved in the maturation of prosomatostatin to somatostatin-14 but not in the somatostatin deficit in Alzheimer's disease. Neuroscience 122 (2003) 437-447
73. Yakovleva T, Bazov I, Cebers G, Marinova Z, Hara Y, Ahmed A, et al. Prodynorphin storage and processing in axon terminals and dendrites. FASEB J, in press.
74. Zhu X., and Lindberg I. 7B2 facilitates the maturation of proPC2 in neuroendocrine cells and is required for the expression of enzymatic activity. J Cell Biol 129 (1995) 1641-1650